用于改善心肌梗塞的ROS响应药物释放注射微凝
Shuqin Wang1, Yuejun Yao1, Liang Song1
1MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310058, China.
Biomaterials
|March 22, 2024
概括
可注射的微凝将促炎细胞转化为调节性T细胞 (Tregs),改善心脏病发作 (心肌梗塞) 后的结果. 这种新的治疗方法可以减少炎症并促进心脏的修复.
科学领域:
- 生物材料科学 生物材料科学
- 免疫学 免疫学 免疫学
- 再生医学是一种再生医学.
背景情况:
- 调控性T细胞 (Treg) 疗法显示出前景,但在细胞可用性和组织向方面面临挑战.
- 现有的Treg疗法因细胞数量低和位特异性差而受到限制,阻碍了临床疗效.
研究的目的:
- 开发一种可注射,释放药物的微凝系统,用于增强Treg治疗.
- 研究微凝在转化促炎Th17细胞到抗炎Tregs中的有效性.
- 在心肌梗塞 (MI) 模型中评估这些微凝的治疗潜力.
主要方法:
- 使用同轴毛细管微流体和紫外线固化制造的可注射药物释放微凝 (MTK-TK-药物).
- 在实验室中评估了微凝介导的Th17细胞转化为Tregs,由活性氧物种 (ROS) 刺激.
- 评估了微凝对心肌细胞亡,炎症,纤维化,血管化和心脏功能在后心脏病发作动物模型的影响.
主要成果:
- 球形微凝 (150微米) 已成功制造,并证明Th17细胞在体外有效转化为Tregs.
- 微凝的ROS清除特性调节了炎症微环境,增强了治疗效果.
- 在体内,微凝显著降低了心肌细胞亡,炎症反应和心脏病后纤维化,同时促进血管化和保持心脏功能.
结论:
- 开发的MTK-TK-药物微凝为Treg疗法提供了一个有前途的策略,通过使细胞在位转化并调节炎症环境.
- 这种微凝系统有效地减轻了炎症,并在心肌梗塞的早期阶段改善了治疗结果.
- 这些发现突出了这些智能微凝在心血管疾病中再生医学应用的潜力.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:18Drug Delivery: Enteral Route
437
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
437
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
500
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
500
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578